No­var­tis faces one win, one loss in patent cas­es over block­buster heart fail­ure drug

No­var­tis record­ed both a win and a loss last week in patent fights over its block­buster heart drug En­tresto.

On Ju­ly 6, a fed­er­al court fort the North­ern Dis­trict of West Vir­ginia ruled in fa­vor of No­var­tis in a patent case against My­lan that was more than three years in the mak­ing. No­var­tis sued My­lan in 2019, ac­cus­ing the biotech of patent in­fringe­ment af­ter it filed an ab­bre­vi­at­ed new drug ap­pli­ca­tion for var­i­ous dos­es of an En­tresto gener­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER